Evaluation of the effect of Empagliflozin on blood glucose, BMI, HbA1c and insulin dose in patients with type 1 diabetes
Not Applicable
Recruiting
- Conditions
- Diabetes type 1.Type 1 diabetes mellitus
- Registration Number
- IRCT20130610013612N12
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Type 1 diabetes
Age over 18 years and less than 30 years
Able to measure blood sugar daily
Be able to measure daily urine ketones
HbA1C between 7.5% - 8.5%
Exclusion Criteria
Kidney failure
Active infection
urinary infection
pregnancy
Cortone use
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin A1c. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Fasting Blood Sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Electrochemiluminescence Test.;2 hour Post Prandial. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: weight scale and stadiometer.
- Secondary Outcome Measures
Name Time Method